SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device
company and manufacturer of the only touchscreen insulin pumps available
in the United States, today announced the closing of its previously
announced underwritten public offering of 30 million shares of common
stock at a price to the public of $2.00 per share. In addition, the
underwriters fully exercised an option to purchase 4.5 million
additional shares of common stock at the public offering price. All of
the shares in the offering were offered by Tandem, with gross proceeds
to Tandem of $69 million from the offering of an aggregate of 34.5
million shares.
Oppenheimer & Co. Inc. acted as the sole book-running manager for the
offering. National Securities Corporation, a wholly owned subsidiary of
National Holdings Corporation (NasdaqCM: NHLD), acted as a co-manager in
connection with the offering.
A registration statement on Form S-1 relating to these securities was
filed by Tandem with the Securities and Exchange Commission and declared
effective on February 8, 2018. A copy of the final prospectus may be
obtained from: Oppenheimer & Co. Inc. Attention: Syndicate Prospectus
Department, 85 Broad St., 26th Floor, New York, NY 10004, by
telephone at (212) 667-8563 or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a medical device company dedicated to
improving the lives of people with diabetes through relentless
innovation and revolutionary customer experience. The Company takes an
innovative, user-centric approach to the design, development and
commercialization of products for people with diabetes who use insulin.
Tandem manufactures and sells the t:slim X2™ Insulin Pump, the only pump
capable of remote feature updates using a personal computer, now
available with Dexcom G5® Mobile continuous glucose
monitoring (CGM) integration, and the t:flex® Insulin Pump,
the first pump designed for people with greater insulin requirements.
Tandem is based in San Diego, California.
t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2
is a trademark of Tandem Diabetes Care, Inc. Dexcom G5 is a registered
trademark of Dexcom, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180213006518/en/
Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media
